European Respiratory Society statement on long COVID follow-up.
Katerina M AntoniouEirini VasarmidiAnne -Marie RussellClaire AndrejakBruno CrestaniMarion DelcroixAnh Tuan Dinh-XuanVenerino PolettiNicola SverzellatiMichele VitaccaMartin WitzenrathThomy ToniaAntonio SpanevelloPublished in: The European respiratory journal (2022)
Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient's quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions. A targeted search of the literature defined the timeline of "long COVID" as 1-6 months post-infection and identified clinical evidence in the follow-up of patients. Studies meeting the inclusion criteria report an association of characteristics of acute infection with persistent symptoms, thromboembolic events in the follow-up period, and evaluations of pulmonary physiology and imaging. Importantly, this statement reviews QoL consequences, symptom burden, disability and home care follow-up. Overall, the evidence for follow-up care for patients with long COVID is limited.
Keyphrases
- coronavirus disease
- respiratory syndrome coronavirus
- sars cov
- end stage renal disease
- healthcare
- chronic kidney disease
- ejection fraction
- newly diagnosed
- palliative care
- liver failure
- peritoneal dialysis
- multiple sclerosis
- systematic review
- quality improvement
- prognostic factors
- intensive care unit
- pain management
- high resolution
- patient reported
- randomized controlled trial
- atrial fibrillation
- physical activity
- depressive symptoms
- cancer therapy
- photodynamic therapy
- drug delivery
- extracorporeal membrane oxygenation
- risk factors
- aortic dissection